Brachytherapy最新文献

{"title":"PO45","authors":"Shubhangi Shah, Xiaoyan Deng, Emma Fields, Dipankar Bandyopadhyay, Bridget Quinn","doi":"10.1016/j.brachy.2023.06.146","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.146","url":null,"abstract":"Purpose Endometrial cancer (EC) is the most common gynecologic malignancy and the fourth most common cancer in women [1]. Treatment is composed of a total hysterectomy, possibly followed by adjuvant chemotherapy or radiation therapy (RT) based on risk factors and staging [2]. Consistent follow up after treatment is integral to assessing for both toxicities and recurrence. Encouraging adjuvant vaginal dilator use has been shown to prevent vaginal stenosis, a common side effect of both surgery and RT [2]. However, about 9% of the female population in the USA face significant geographical barriers to receiving gynecologic cancer treatment [3]. Furthermore, previous studies showed being over 50 miles from a high-volume hospital was associated with increased risk of non-adherence care and increased mortality [4]. Increased time from endometrial biopsy to surgery is one documented factor that increased risk of poor outcomes [5]. This retrospective study evaluates if geographical location is associated with access to endometrial cancer care and post-radiation vaginal stenosis. Materials and Methods Patients enrolled in the study underwent surgery +/- RT for Stage I-IIIC endometrial cancer. Vaginal dilator use was recommended to all patients receiving RT. Vaginal length at follow up visits was measured with a vaginal sound. Data from patient charts was used to determine patient demographics, location, and follow up care. Results Forty-two patients had sufficient data for analysis. Average distance from the treatment hospital was 40.9 miles, 54% of patients lived in an urban county. Average number of days from an endometrial biopsy to surgical treatment was 43 days. Living >80 miles from the hospital was associated with an 80% increase in the days between an endometrial biopsy and surgery, compared to those living within 20 miles (p<0.01). Average months of follow up after surgery was 31. There was no impact of an increased distance from the hospital affecting months of follow-up care, vaginal stenosis, or dilator adherence. Conclusions This study provides evidence that living extreme distances from a high-volume cancer center is associated with delayed access to care. Furthermore, there's no direct impact of geography on post-RT vaginal dilation or adherence to care. Our findings suggest reduced discrimination in EC care despite geographical barriers. Further studies to evaluate impact of geography on mortality rates are needed. References: 1. BRAUN MM, OVERBEEK-WAGER EA, GRUMBO RJ. Diagnosis and Management of Endometrial Cancer. Am Fam Physician. 2016;93(6):468-474. Accessed January 30, 2023. https://www.aafp.org/pubs/afp/issues/2016/0315/p468.html2. Quinn, BA, et al. Change in Vaginal Length and Sexual Function in Women Who Undergo Surgery ± Radiation Therapy for Endometrial Cancer . Brachytherapy, 2023. In press.3. Shalowitz DI, Vinograd AM, Giuntoli RL. Geographic access to gynecologic cancer care in the United States. Gynecol Oncol. 2015;138(1):115-","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PO09","authors":"Sergej Sergeich Romanenko","doi":"10.1016/j.brachy.2023.06.110","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.110","url":null,"abstract":"According to our experience, intracavitary brachytherapy of metastasis into vagina is not effective, especially in the case of volumetric tumor. As a rule we use intratissue brachytherapy with an intracavitary applicator of maximal diameter. Patient and Methods In 2020 Ca of transverse colon was diagnosed in a patient 58 years old, female. Ultrasonography, CT, MRI investigations and biopsy confirmed mts in both ovarian, pathological retroperitoneal, mesenteric and intracranial lymph nodes, left lobe of liver. First line of treatment included surgery, chemotherapy and hormone therapy. Operations: median laparotomy, right-sided hemicolectomy, atypical resection of the left lobe of liver. Chemotherapy (14 courses) - 8 courses with oxaliplatin and capecitabine and 6 courses with irinotecan. Mts into vagina were revealed a month after completing the treatment. 39,6 Gy (2.2 Gy*18 fractions) to pelvis with concomitant intracavitary brachytherapy 7Gy*4, total dose 28 Gy with normalization 5 mm from mucosa was delivered. In three months volumetric lesion in vagina right wall was confirmed at CT scans and visually. Intratissue brachytherapy with rigid needles was decided to use. Dose distribution and needle location is shown at the Figure. Needle insertion was done by freehand under anesthesia. Doses amounted to 30 Gy (1 time per week, 10 Gy fraction). Treatment was carried out at Microselectron 30 channels on the base of CT scans. Radiation reactions (burning and profuse discharge) lasted one month approximately. Results In 3 months CT with contrast did not show the presence of pathological foci in the body. And visually vagina had no signs of a tumor. Conclusion It was shown that intratissue brachytherapy is effective in the treatment of tumors affecting vagina. According to our experience, intracavitary brachytherapy of metastasis into vagina is not effective, especially in the case of volumetric tumor. As a rule we use intratissue brachytherapy with an intracavitary applicator of maximal diameter. In 2020 Ca of transverse colon was diagnosed in a patient 58 years old, female. Ultrasonography, CT, MRI investigations and biopsy confirmed mts in both ovarian, pathological retroperitoneal, mesenteric and intracranial lymph nodes, left lobe of liver. First line of treatment included surgery, chemotherapy and hormone therapy. Operations: median laparotomy, right-sided hemicolectomy, atypical resection of the left lobe of liver. Chemotherapy (14 courses) - 8 courses with oxaliplatin and capecitabine and 6 courses with irinotecan. Mts into vagina were revealed a month after completing the treatment. 39,6 Gy (2.2 Gy*18 fractions) to pelvis with concomitant intracavitary brachytherapy 7Gy*4, total dose 28 Gy with normalization 5 mm from mucosa was delivered. In three months volumetric lesion in vagina right wall was confirmed at CT scans and visually. Intratissue brachytherapy with rigid needles was decided to use. Dose distribution and needle location is shown ","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"184 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PO78","authors":"Karel Arthur Hinnen, Iris Kuitems, Robbert Den Butter, Benjamin Arnods, Theo De Reijke, Zdenko Van Kesteren, Jette Bloemberg, Paul Breedveld, Bradley Pieters","doi":"10.1016/j.brachy.2023.06.179","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.179","url":null,"abstract":"","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"79 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author Index of the Abstracts of the 2023 American Brachytherapy Society Annual Meeting","authors":"","doi":"10.1016/j.brachy.2023.09.003","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.09.003","url":null,"abstract":"","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PO84","authors":"Margaret Barker, Michael Campbell, Lisa Turner, A． Nisar M. Syed, Randy Wei, Peyman Kabolizadeh","doi":"10.1016/j.brachy.2023.06.185","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.185","url":null,"abstract":"Purpose Interstitial HDR brachytherapy involves precise, localized delivery to a high risk clinical target volume (HRCTV) with high dose gradients, sparing adjacent critical organs at risk (OAR). Due to the proximity of the rectum and bladder to the HRCTV, deviations in the applicator or catheter with respect to patient anatomy can change dose to those structures. Utilizing plastic interstitial catheters allows the patient to receive hyperthermia therapy during their course of interstitial treatment, however, the plastic catheters were observed to show significant deflection when the metal stylets are removed for treatment. The hyperthermia electrodes and the HDR source cable are both wires of approximately the same thickness. The purpose of this study is to assess the magnitude and deflection of the plastic catheters for gynecologic interstitial plans and determine whether using flexible wires for visualization on pre-treatment imaging is suitable for reconstructing the actual treatment received. Materials and Methods Eight patients with a total of 16 plans with re-treatment CT images where the metal stylets were utilized for plastic catheter (Best Medical) visualization were registered to a subsequent CT scan with the metal stylets removed. The originally planned (Brachyvision, Varian) treatment dwell positions and times were adjusted to the second CT to evaluate three-dimensional catheter displacement and dose distributions calculated for the bladder, rectum, and target. Results Absolute 3D displacement for all patients was 3.5 mm ± 5.4 mm (n = 3217 catheter dwell positions for all treatment plans and patients, mean ± SD, p < 0.001) comparing plans with the stylet in versus out. Absolute catheter deflection magnitude for interstitial treatments increased with the removal of the metal stylets with a difference of 0.75° ± 0.49° (n = 299 catheters for all treatment plans and patients, mean ± SD, p < 0.01). The plans were subsequently reconstructed on a pre-planning CT with flexible 20-gauge wires instead of metal stylets and are observed to correlate with the plans with no stylets with absolute 3D displacement and angular deflection of 1.1 ± 0.6 mm and 0.35 ± 0.3 respectively (n = 39 catheters, mean ± SD, p > 0.2). While the average target EQD2 D90 reduced by 5% ± 5%, four patients would have experienced a deviation from the prescription by >10%. There was an overall decrease in bladder D2cc and overall increase in rectal D2cc in the plans with the stylets removed. Conclusions Catheter reconstruction in interstitial gynecological treatments with CT imaging revealed significant changes in catheter positioning with respect to the target volume once the stylets are removed for treatment. Using flexible wires of similar thickness to the source cable allow for more accurate tracking during planning without distorting the final treatment plan. Interstitial HDR brachytherapy involves precise, localized delivery to a high risk clinical target volume (HRC","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"61 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PO37","authors":"Michael Salerno, Rachel Trevillian, Shibu Anamalayil, Megan Kassick, Seung Won Seol, Neil Taunk, Emily Hubley","doi":"10.1016/j.brachy.2023.06.138","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.138","url":null,"abstract":"Purpose Treating multiple fractions of cervical HDR BT with a single implant can reduce the overall package time of the procedure and reduces patient anesthesia and radiation oncology personnel resources due to reduced numbers of plans generated. Intracavitary (IC) and Intracavitary/Interstitial (IC/IS) applicators can shift between brachytherapy fractions, and bladder and bowel filling can cause interfraction variations of OAR dosimetry. Interfraction dosimetry variations of single implants have not been well-quantified and it is unclear whether an adaptive replan is required for each fraction. Methods and Materials 10 patients with locally advanced cervical cancer treated with HDR BT were included in this study: 5 consecutive IC (T&R applicator) and 5 consecutive hybrid IC/IS (T&R with interstitial needles). Each patient received 45Gy in 25 fractions of EBRT followed by 28Gy in 4 fractions of HDR MR-IGABT with Alatus Vaginal Balloon packing (Radiadyne, Latham, NY). BT was administered using a two-implant technique. After the first implant, fraction 1 was planned and delivered using CT and MRI. After overnight admission, a new CT was obtained prior to fraction 2 and rigidly registered to the fraction 1 CT using the applicator and cervix as landmarks. The bladder, rectum, and sigmoid colon were contoured and the treatment plan for fraction 1 was copied onto the fraction 2 CT. The same procedure was applied for fractions 3 and 4 with a new implant followed by a CT/MR-based plan generated for fraction 3, and an evaluation CT for fraction 4. The absolute interfraction change in EQD2 and cumulative EBRT+BT was calculated using an alpha/beta value of 3; all doses are reported in EQD2. Differences in interfraction variability between IC and IC/IS plans were investigated. Results The mean HRCTV volume was 17.8cc (8.1-27cc) for IC plans and 32.6cc (19.6-44.4cc) for IC/IS plans. All IC/IS plans had an average fraction of total dwell time of less than 20% in needles. The D2cc for bladder, rectum, and sigmoid were below the soft/hard EMBRACE II guidelines for all plans (80/90Gy, 65/75Gy, 65/75Gy, respectively). The mean single BT fraction D2cc to bladder, rectum, and sigmoid were 7.9Gy, 2.9Gy and 4.2Gy. The bladder D2cc displayed the greatest interfraction variability, with an average absolute interfraction difference of 1.8±1.3Gy, while rectum and sigmoid were 0.6±0.5Gy and 0.7±0.7Gy. Differences between IC and IC/IS plans were also compared. The mean single fraction D2cc to bladder was lower for IC/IS plans (7.2±1.0Gy) as compared to IC plans (8.7±0.4Gy). The mean single fraction D2cc to rectum and sigmoid were similar between the two methods (2.8±0.3Gy and 4.3±0.3Gy for IC/IS versus 2.9±0.3Gy and 4.1±0.3Gy for IC). The absolute interfraction D2cc difference was minimal with both applicators (Figure 1). The interfraction D2cc difference to bladder, rectum, and sigmoid was similar for IC/IS plans (1.8±1.1Gy, 0.6±0.5Gy and 0.7±0.8Gy) as compared to IC plans","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PO98","authors":"Gopishankar Natanasabapathi, Dayanand Sharma, Vellaiyan Subramani, Surendra Kumar Saini, Dhanabalan Rajasekaran","doi":"10.1016/j.brachy.2023.06.199","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.199","url":null,"abstract":"Purpose Development of brachytherapy template as a radiation treatment guidance device to localize deep seated tumors. Materials and Methods The template of specific size and dimension were designed using solid modeling computer-aided design (Solid Works, Dassault systemes). The design was further converted to 3D printing readable format (. stl format). All the parts of the design were printed in 3D printer (Phrozen Technology, Taiwan) using stereolithography technology (SLA). A resin material in liquid form was laid on the 3D printer platform for printing. Lifting speed of the printing plate was set at 40 mm/min. The retract speed was 150 mm/min. The exposure time was set at 3.5 s. The newly designed template with all accessories were scanned in an X-ray CT scanner for imaging compatibility purpose. Scanning parameters were as follows: Tube Voltage - 120 kV, slice thickness - 2.0 mm, Tube Current - 305 mA, pixel size - 0.6738 x 0.7638 mm2 and etc. Results The overall process took 3 hours to print the design with printing resolution of 50 microns. Various parts of the design were produced in a layer-by-layer fashion. By photochemical process, the chosen resin material cross-linked together to form polymers. In the imaging study the Hounsfield unit (HU) value of the resin material for template design was found to be 250 HU. The newly printed template had angled holes around 80 degrees to insert and maneuver interstitial needles. The template design was built in such a way that obturators, rectal probe and related accessories were easily positioned and immobilized in the template capable of tumor localization in real clinical situation. A rectal probe was built as well with the base template. Conclusions We are further developing a human pelvis phantom to test the efficacy of the new 3D printed template which we will show in our future studies. The ultimate goal of this study is to personalize patient treatment with an affordable and cost-effective solution. The newly designed template is capable of performing brachytherapy procedure. Further dosimetric validation study is required to explore the potential of the template for clinical use purpose. Development of brachytherapy template as a radiation treatment guidance device to localize deep seated tumors. The template of specific size and dimension were designed using solid modeling computer-aided design (Solid Works, Dassault systemes). The design was further converted to 3D printing readable format (. stl format). All the parts of the design were printed in 3D printer (Phrozen Technology, Taiwan) using stereolithography technology (SLA). A resin material in liquid form was laid on the 3D printer platform for printing. Lifting speed of the printing plate was set at 40 mm/min. The retract speed was 150 mm/min. The exposure time was set at 3.5 s. The newly designed template with all accessories were scanned in an X-ray CT scanner for imaging compatibility purpose. Scanning parameters were as follow","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PO10","authors":"Suneetha Mulinti, Mahaboob Basha Syed, Naga Satish Golla, Chandra Kumar Racharla, Sushil Beriwal","doi":"10.1016/j.brachy.2023.06.111","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.111","url":null,"abstract":"Purpose Clinicians at Aarhus University Hospital, Denmark developed the individualized 3D printed needle templates and Varian worked with Aarhus to develop this hybrid applicator with standard needle template. We started using this in our practice in 2022 and present our initial experience using this Aarhus ring and tandem MR compatible hybrid interstitial applicator with both straight and oblique needles in patients with locally advanced cervical carcinoma. Materials & Methods A total number of 22 patients from stage IB3 to IIIB were treated with MR based Image guided adaptive brachytherapy between March 2022 to January 2023, of which 17 patients were treated with Hybrid Interstitial brachytherapy with Aarhus applicator after completion of External Beam Radiotherapy. All patients were treated with External Beam radiation to a dose of 45 to 50 Gy in 25 fractions with SIB (55 Gy) to gross nodes along with concurrent weekly chemotherapy with Cisplatin @40 mg/m2. This was followed by brachytherapy to a total dose of 21 - 28 Gy in 3 to 4 fractions of IGABT with planning aims of HRCTV - D90 to receive > 85 to 90 Gy and keeping the EQD2 for 2cc Rectum, Sigmoid and Bladder to < 65 - 70 Gy, 70 - 75 Gy and 80 -85 Gy respectively. Each patient had 2 insertions of brachytherapy with 1 to 2 fractions with each insertion, done under short General anesthesia using real time trans abdominal USG guidance. Results A total number of 62 fractions have been performed with a median number of 4 (range 1-5 needles per patient. 8 patients required oblique needles. The average time from insertion to the first fraction treatment was 4 hours. Six hours gap was given between the two fractions done on same day. No acute Grade 3 complications have been recorded including bleeding or organ perforation. The Median EQD2 D90 of HRCTV was 91.77 Gy [80.1 to 101.9 Gy] and Median GTVp dose D98 was 110.12 Gy [81.1 to 123.5 Gy]. Median EQD2 for 2cc Bladder was 77.75 Gy [65.48 to 80.73Gy], Rectum was 56.36 [40.76 to 66.39Gy], Sigmoid colon - 61.18 Gy [52.24 to 72.88Gy], Small bowel - 58.4 [51.98 to 63.42Gy] 12 out of 17 patients completed first follow up at 3 months, out of which 11 patients showed complete response at cervix. Conclusion Our initial results show excellent dosimetry and no significant procedure related complications with MRI based IGABT in our clinic using hybrid applicator. Clinicians at Aarhus University Hospital, Denmark developed the individualized 3D printed needle templates and Varian worked with Aarhus to develop this hybrid applicator with standard needle template. We started using this in our practice in 2022 and present our initial experience using this Aarhus ring and tandem MR compatible hybrid interstitial applicator with both straight and oblique needles in patients with locally advanced cervical carcinoma. A total number of 22 patients from stage IB3 to IIIB were treated with MR based Image guided adaptive brachytherapy between March 2022 to January 2023, ","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PO36","authors":"Memory Fadziso Bvochora-Nsingo, Rohini Bhatia, Elliphine Gwangwava, Masud Rana Khan, Thabiso Itshabeng, Surbhi Grover","doi":"10.1016/j.brachy.2023.06.137","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.137","url":null,"abstract":"Purpose Cancer of the cervix is the most common malignancy treated at Gaborone Private Hospital, the only facility with radiotherapy in Botswana. Patients are treated with both curative and palliative intent. Curative patients are offered concurrent chemoradiotherapy followed by high dose rate brachytherapy. Palliative patients receive external beam radiation, commonly using AP-PA fields. Doses range from 8Gy Single fraction to 30Gy in ten fractions over two weeks. We report a patient receiving hemostatic high dose rate brachytherapy using intrauterine tandem insertion only. Materials and Methods In April 2022, a 43-year-old patient, HIV positive and virally suppressed, was referred to us with a four day history of severe vaginal bleeding. She had had a biopsy two months prior to presentation proving invasive squamous cell carcinoma of the cervix. She was staged as 4A with frozen pelvis and was on the waiting list for palliative radiation. However, the linear accelerator was down, and we were awaiting the engineer from neighboring South Africa. The patient had already been transfused a total of ten units of packed cells, three having been transfused the day prior to presentation. Her renal function was normal, and hemoglobin was 9g/dl. The patient presented in a stable condition with ECOG PS of two. After a quick history and physical examination, the patient gave signed consent for haemostatic brachytherapy. Vital signs were normal with blood pressure 100/60 mmHg, pulse 88 beats per minute and no fever. She was pre medicated with Cyclokapron 1 gram IV, Oxynorm 10 mg po, Paracetamol 1g IV and sedated with bromazepam 3mg po stat. A large bore cannula was inserted and a drip with IV Ringers lactate was inserted for slow infusion. Under sterile conditions, speculum showed a bulky cervical mass more than 8cm. Gentle probing with uterine sound identified the os. An 8cm tandem was inserted into the uterus (blind insertion no ultrasound guidance) and packing was done to stabilize the tandem. A CT scan was performed, and the images were transferred to the Nucleotron High Dose Rate Unit. A target volume was outlined on CT images. Since there was extensive rectal/ sigmoid and bladder invasion no OARs were contoured. (Fig 1). A plan was generated delivering 5.7 Gy to most of the GTV (EQD2 8Gy). The instruments were removed, and vaginal packing was done to stay overnight. Results The treatment was well tolerated and on completion of the treatment vaginal bleeding had stopped. Time from consultation to completion of treatment (i.e. haemostasis) was less than 90 minutes. Removal of vaginal pack the next morning showed no fresh bleeding. The patient reported vaginal spotting on day 3 when passing stool. Telephonic consultation after two weeks and one month confirmed no vaginal bleeding. The patient was referred back for consideration of colostomy so she could be assessed for further treatment. Conclusion In this patient we demonstrated that brachytherapy is an e","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PO75","authors":"Fred J. Schnell, Steven Schnell, Mark Quinn","doi":"10.1016/j.brachy.2023.06.176","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.176","url":null,"abstract":"Purpose The purpose of this study is to determine the efficacy of high dose-rate brachytherapy as a single modality treatment in patients with low and intermediate risk prostate cancer in a community setting. Materials and Methods Data was collected from 114 patients who were consecutively treated and received high dose-rate brachytherapy monotherapy for low and intermediate risk prostate cancer from 01/18/2017 to 12/14/2021. Patients had a median age at the start of treatment of 69, with a mean of 68.09 and range of 46 to 95 years. The clinical stage for all patients was T1c, with seventy-four (64.91%) patients having a Gleason score of 3+3=6, thirty-seven (32.46%) having a Gleason score of 3+4=7, and three (2.63%) having a Gleason score of 4+3=7. No patients exhibited perineural invasion and only five (4.39%) had 50% or more cores positive. The pretreatment PSA levels of all patients were between 2.2 and 17.5 ng/mL, with a median and mean of 5.8 and 6.7 ng/mL, respectively. Patients were administered either 3,800 cGy in two, three, or four fractions or 3,600 cGy in four fractions using HDR Iridium-192 as the radiation source. 104 patients (91.23%) received a dose of 3,800 cGy in four equal fractions, one patient (0.88%) in three equal fractions, and four patients (3.51%) in two equal fractions. Five patients (4.39%) received a dose of 3,600 cGy in four fractions. Patients receiving four fractions were given two fractions per day, two weeks apart, while patients receiving two fractions were given one fraction per day, two weeks apart. Following treatment, patients had scheduled follow-ups every three to six months after treatment to determine PSA levels. Results Post-treatment PSA levels were recorded for 108 patients, and this data was used to calculate a cure rate using the Phoenix definition of biochemical failure: a rise in PSA level 2.0 ng/mL above nadir. The definition used for a benign bounce is a rise in PSA level followed by a subsequent decrease in PSA level by greater than or equal to 0.5 ng/mL. PSA nadirs were recorded an average of 544.52 days after the end of treatment. There was a range of 85 to 1099 days and a median of 538.5 days. The average post-treatment PSA nadir was 0.83 ng/mL with a median of 0.50 ng/mL and range of less than 0.01 ng/mL to 4.51 ng/mL. Twenty-one (19.44%) of patients achieved a nadir value between 0.5 and 1.0 ng/mL, and fifty-one (47.22%) achieved a nadir value of below 0.5 ng/mL. Two patients experienced biochemical failure according to the Phoenix definition, as their PSA level rose 2.0 ng/mL above nadir with no subsequent decrease, resulting in a 98.15% success rate. Conclusions High dose-rate brachytherapy as a single modality treatment is successful in a community setting in treating low and intermediate risk prostate patients. The purpose of this study is to determine the efficacy of high dose-rate brachytherapy as a single modality treatment in patients with low and intermediate risk prostate cancer ","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"59 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}